Oxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins by Brea López, David et al.
Brea et al. BMC Neurology 2012, 12:65
http://www.biomedcentral.com/1471-2377/12/65RESEARCH ARTICLE Open AccessOxidative stress markers are associated to
vascular recurrence in non-cardioembolic stroke
patients non-treated with statins
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Background: Since atherogenesis is related to oxidative stress, our objective was to study the association of
oxidative stress markers with the vascular recurrence in non-cardioembolic stroke.
Methods: Atherosclerotic and oxidative stress markers were evaluated on admission, in 477 patients suffering from
a first non-cardioembolic stroke. Patients were followed at 6 and 12 months after inclusion, recording cardiovascular
events. As markers of endothelial oxidative stress we used oxidized LDL, Cu/Zn superoxide dismutase and 8-OH
deoxiguanosine. 136 patients were being treated with statins at the moment of serum samples acquisition.
Results: Patients who suffered vascular recurrence or vascular-origin death had higher levels of 8-OHDG (40.06
±24.70vs33.11±15.18;p=0.003). We also found associations between vascular recurrence or vascular origin death and
Cu/ZnSOD (OR,1.02; 95%CI,1.00-1.03;p=0.0001) and 8-OHDG (OR,1.12;95%CI,1.08-1.16;p<0.0001) in a subgroup of 333
patients that were not in treatment with statins on admission. We also found associations between 8-OHDG and
intima media thickness (IMT) (OR,1.13;95%CI,1.09-1.16;p<0.0001), presence of ipsilatieral stenosis≥50% (OR,1.03;95%
CI1.00-1.05;p=0.007) and other atherosclerotic plaque characteristics.
Conclusions: Specific oxidative stress markers were found to be markers of atherosclerosis plaque types and
vascular recurrence in non-statins treated patients at admission.
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Atherosclerosis and atherothrombosis involve inflamma-
tion, oxidative stress, plaque disruption, platelet activation
and aggregation, and thrombus formation. Thrombosis
superimposed on progressive narrowing of atherosclerotic
arteries may result in sudden arterial occlusion or in
microembolization leading to acute coronary syndrome,
ischemic stroke, transient ischemic attack, or other symp-
toms [1,2].
Atherothrombosis is associated with significant mor-
bidity and mortality, both from the initial and subse-
quent secondary vascular events, especially within the
first year [3]. It has previously been shown that, the risk* Correspondence: jose.castillo@usc.es
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reproduction in any medium, provided the orof vascular recurrence within the first year after a first
stroke is 15 times higher than the risk in the general
population [4]. In addition, if we only consider non-
cardioembolic stroke patients, 20-40% of patients will
suffer recurrence within five years after the first stroke event
[4]. However, there are no markers that allow the identifica-
tion of patients at high risk of vascular recurrence.
Atherogenesis is associated with oxidative stress and
reactive oxygen species. The generation of reactive oxy-
gen species (ROS) is important in both normal physi-
ology and in the pathogenesis of many diseases.
Accumulation of ROS may be accompanied by the pro-
duction of reactive nitrogen species. Under physiological
conditions, cells defend themselves against ROS damage
through antioxidants that remove free radical intermedi-
ates and inhibit oxidation. An imbalance between en-
dogenous oxidants and antioxidants results in oxidative. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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atherogenesis [5].
Oxidative stress plays a key role at several steps of
atherogenesis. Thus, for example LDL is oxidatively
modified by endothelial cells, vascular smooth muscle
cells, and monocytes. Macrophages within the vessel wall
internalize ox-LDL via scavenger receptors, and develop
into lipid-rich “foam cells”. Evidence that LDL oxidation
occurs in vivo is supported by the reaction of ox-LDL
antibodies with atherosclerotic lesions [6]. Other
enzymes or markers of oxidative stress are also import-
ant in atherogenesis process. In addition to ox-LDL,
enzymes that participates in oxidative stress regulation,
for example superoxide dismutase (SOD), are increased
in atherosclerotic lesions and colocalized with lipid-laden
macrophages in atherosclerotic vessels of apo(E)-defi-
cient mice [7].
Since oxidative stress participates in the atherogenesis
process and this process is an important cause of recur-
rence in non-cardioembolic stroke, our aim was to
analyze the association of several markers of oxidative
stress with the recurrence of vascular events and with
atherosclerotic plaque characteristics.
Results
Population characteristics
Four hundred seventy seven independent patients older
than 60 years suffering from a first non-cardioembolic
stroke were included in the study (76.9% of total patients).
The mean age of these patients was 71.8 ± 7.5 years; 331 of
them were men (69.39%). Distribution by stroke subtype
was 61.43% atherothrombotic (n= 293), 19.70% lacunar
(n= 94) and 18.87% were cryptogenic (n= 90) (Table 1).
Levels of oxidative stress markers at admission on this
group of patients were; 54.72 [45.53–68.74] ng/mL for
oxLDL, 46.12 [31.56-71.21] ng/mL for Cu/Zn SOD, and
34.10± 17.01 ng/mL for 8-OHDG. 136 patients (38.5%)
were in treatment with statins at admission. These patients
had greater percentage of vascular risk factors and lower
levels of 8-OHDG.
The study was approved by the ethical committee of
each centre and informed consent was obtained from
patients or relatives.
Primary endpoint; vascular recurrence or vascular origin
death and oxidative stress markers
Univariate analysis revealed association between systolic
blood pressure (p = 0.017) symptomatic PAD (p < 0.0001),
stroke subtype (p < 0.0001), mRS on discharged
(p = 0.034), ABI (p < 0.0001), IMT (p = 0.043), ipsilateral
stenosis in ICA (p < 0.0001), contralateral stenosis in ICA
(p = 0.004), and plaque surface (P = 0.001) and higher risk
of vascular events on follow-up. In addition, patients
who suffered vascular recurrence or vascular death hadhigher levels of 8-OHDG (40.06 ± 24.70 vs 33.11 ± 15.18;
p = 0.003). However, no differences were found in ox-
LDL on admission (53.43 [43.34-62.52] vs 54.83 [45.71-
69.36]; p = 0.241) or Cu/Zn SOD on admission (52.75
[36.73-89.59] vs 44.37 [31.06-70.06]; p = 0.062). Logistic
regression analysis including all significant variables in
the univariate analysis revealed no independent associ-
ation between 8-OHDG levels and vascular recurrence
or vascular death(OR, 1.02; 95%CI, 0.94-1.04; p = 0.197).
When the primary endpoint was categorized in
vascular-origin death, non-vascular origin death, vascular
recurrence and non-events, association was found with
Cu/ZnSOD (65.84 [33.80-111.99], 52.59 [27.94-63.40],
52.18 [37.09-96.43], 44.37 [31.06-70.06] respectively;
p = 0.027 for all comparison) and with 8-OHDG
(32.04 ± 25.17; 36.69 ± 18.03; 41.46 ± 25.20; 33.11 ± 15.18
respectively; p = 0.009 for all comparison), but not with
ox-LDL (p = 0.706).
Secondary endpoint; atherosclerotic markers and
oxidative stress markers
Since oxidative stress markers could be associated with
atherogenesis and atherosclerotic plaque progression, we
analyzed the association between ox-LDL, Cu/Zn SOD
and 8-OHDG and atherosclerotic markers, such as ABI,
IMT, stenosis grade and plaque echogenicity. No associ-
ation was found between ABI and oxidative stress mar-
kers that were analyzed (ox-LDL, Cu/Zn SOD or 8-
OHDG). Association was found between IMT and Cu/
ZnSOD (Spearman coefficient 0.099, p = 0.034) and be-
tween IMT and 8-OHDG (Pearson coefficient 0.133;
P = 0.004). When IMT was categorized in IMT< 1.1 mm
or IMT≥ 1.1 mm, association was only found for 8-
OHDG (32.60 ± 14.92 vs 38.51 ± 21.55, respectively;
p = 0.001). This association persisted in logistic regres-
sion analysis (OR, 1.02; 95% CI, 1.00-1.03; p = 0.004). No
association was found between oxidative stress markers
and carotid plaques characteristics, such as stenosis or
plaques characteristics (smooth, irregular, ulcerated pla-
ques) (data not shown).
Vascular recurrence and oxidative stress markers in a
subgroup of patients
In a post-hoc analysis we observed that 144 patients
from 477 in which serum sample was available were
being treated with statins at the moment of serum sam-
ple acquisition. Since statins have pleiotropic effects in-
cluding antioxidant properties, we decided to re-analyze
the potential value of oxidative stress markers in the sub-
group of patients that were not treated with statins at
the moment of serum extraction.
Three-hundred and thirty three patients were not
being treated with statins when serum sample was
extracted (mean age 71.29 ± 7.43). Two hundred thirty
Table 1 Baseline clinical characteristics, vascular risk factors, stroke subtype, biochemical parameters and
neuroimaging findings in patients with and without recurrence
Primary end-point
No n= 409 Yes n= 68 p
Age, years 70.9 ± 7.2 71.4 ± 8.2 0.687
Male, % 68.7 73.5 0.479
Weight, kg 75.1 ± 11.8 78.5 ± 14.5 0.106
Waist circumference, cm 101.3 ± 12.6 103.7 ± 14.4 0.203
Systolic blood pressure, mm Hg 152.8 ± 25.2 161.1 ± 26.4 0.017
Diastolic blood pressure, mm Hg 82.9 ± 13.0 85.2 ± 14.3 0.141
Arterial hypertension, % 72.5 69.1 0.562
Diabetes mellitus, % 34.4 45.6 0.078
Active smoker, % 29.6 26.5 0.667
Alcohol intake, % 4.9 8.8 0.242
Dyslipemia, % 44.2 48.5 0.513
Ischaemic CHD, % 11.5 16.2 0.316
Symptomatic PAD, % 6.0 23.5 <0.0001
Treatment before index stroke
Antiplatelets, % 25.2 28.4 0.651
Statins, % 28.6 31.3 0.664
Antihypertensive, % 62.2 60.3 0.788
Hypoglycemics, % 26.9 36.4 0.139
Treatment at discharge
Antiplatelets, % 99.3 100 0.628
Statins, % 73.8 73.5 0.533
Antihypertensive, % 76.8 76.1 0.505
Hypoglycemics, % 33.0 35.3 0.404
Stroke subtype <0.0001
Atherothrombotic probable, % 14.8 35.3
Atherothrombotic posible, % 43.7 41.2
Lacunar, % 21.0 13.2
Cryptogenic, % 20.5 10.3
Modified Rankin at discharge 1 [0, 2] 2 [1, 2] 0.034
ABI 1.00 ± 0.23 0.92 ± 0.29 <0.0001
IMT, mm 0.91 ± 0.34 0.96 ± 0.44 0.043
ICA stenosis > 50 % homolateral, % 14.8 35.8 <0.0001
ICA stenosis > 50 % contralateral, % 5.7 16.4 0.004
Echogenicity of plaques 0.493
Type I, % 15.0 10.7
Type II, % 14.7 17.9
Type III, % 24.5 21.4
Type IV, % 37.9 46.4
Type V, % 8.2 3.6
Plaques surface 0.001
Smooth and even, % 75.0 50.0
Uneven, % 23.7 48.3
Ulcerated, % 1.3 1.7
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Table 1 Baseline clinical characteristics, vascular risk factors, stroke subtype, biochemical parameters and
neuroimaging findings in patients with and without recurrence (Continued)
8-OHDG (ng/mL) 33.11 ± 15.18 40.06 ± 24.70 0.003
Cu/Zn SOD (ng/mL) 44.37[31.06-70.06] 52.75 [36.73-89.59] 0.062
ox-LDL (ng/mL) 54.83 [45.71-69.36] 53.43[43.34-62.52] 0.241
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thrombotic patients (57.95%), 72 were lacunar (21.62%)
and 68 were cryptogenic (21.72%). Levels of oxidative
stress markers at admission on this subgroup of patients
were; 54.92 [45.30-68.41] ng/mL for oxLDL, 47.45 [32.82-
70.78] ng/mL for Cu/Zn SOD, and 39.85 ± 13.97 ng/mL
for 8-OHDG.
In this subgroup of patients, patients who suffered vas-
cular recurrence or vascular death showed higher levels
of Cu/Zn SOD (45.39 [30.99-69.31] vs 54.30[43.60-
92.86]; p = 0.001)) and higher levels of 8-OHDG
(37.40 ± 12.57 vs 55.17 ± 12.56; p < 0.0001) (Figure 1A).
When logistic regression analysis were performed includ-
ing all the significant variables in the univariate analysis
together with oxidative stress markers, association be-
tween vascular recurrence or vascular origin death and
Cu/ZnSOD (OR, 1.02; 95% CI, 1.00-1.03; p = 0.0001) and
8-OHDG (OR, 1.12; 95% CI, 1.08-1.16; p < 0.0001)
persisted.
We also analyzed, in this subgroup of patients, the re-
lationship between oxidative stress markers and athero-
sclerosis markers. We did not find any association
between oxidative stress markers and ABI, however asso-
ciation was found between IMT and 8-OHDG (Pearson
coefficient 0.502, p < 0.0001) (Figure 1A). In addition,
when IMT was categorized in IMT< 1.1 mm or
IMT ≥ 1.1 mm, Cu/Sn SOD (52.57 ± 28.43 vs.
60.45 ± 32.63, p = 0.033) and 8OHDG (36.24 ± 12.92 vs
50.05 ± 11.71 p < 0.0001) were significantly higher in
patients with IMT ≥ 1.1. After adjusting by the significant
variables in the univariate study, association between
IMT ≥ 1.1 and 8-OHDG persisted in logistic regression
analysis (OR, 1.09; 95% CI, 1.06-1.12; p < 0.0001).
Analysis of relationship between oxidative stress mar-
kers and atherosclerotic plaques characteristics, also
showed some positive results. When we analyzed oxida-
tive stress markers in relation to stenosis grade of ath-
erosclerotic plaques, we found that 8-OHDG levels were
higher in patients with stenosis ≥50% in the ipsilateral
carotid (45.42 ± 15.07 vs 38.86 ± 13.55, p = 0.005)
(Figure 1A). In addition we also found that 8-OHDG
was higher in patients with stenosis in the contralateral
carotid (46.36 ± 13.00 vs 39.65 ± 13.90, p = 0.034). How-
ever, when adjusted models were performed, 8-OHDG
only remained associated with the presence of ipsilateral
stenosis ≥50% (OR, 1.03; 95 % CI 1.00-1.05; p = 0.007).
Analyzing plaques types, we observed that 38 patients
showed anechoic plaques (type I), 34 patients showedhypoechoic plaques (type II), 61 patients showed echoic
plaques (type III), 96 patients showed hyperechoic pla-
ques (type IV) and 21 patients showed non-classified pla-
ques (type V). In these groups of patients, 8-OHDG
levels were different with p = 0.002 (35.84 ± 13.66,
40.00 ± 15.21, 38.41 ± 14.92, 45.02 ± 12.76, 37.35 ± 13.54,
respectively) (Figure 1B).
Finally, atherosclerotic plaques were classified accord-
ing to morphology surface in smooth (n = 190), irregular
(n = 68) or ulcerated (n = 2). Analysis of oxidative stress
markers showed significant differences in 8-OHDG levels
with p < 0.0001 in these patients (38.53 ± 13.52;
45.87 ± 14.53; 59.12 ± 25.40 respectively), although the
small number of patients with ulcerated plaques makes
these results suspect (Figure 1B). If plaque surface is
categorized in regular (smooth) and irregular (irregular
plus ulcerated), multivariate analysis does not show inde-
pendent significance for 8-OHDG (OR, 1.14; 95% CI
0.99-1.31; p = 0.069).
Discussion
In this study we have shown that oxidative stress mar-
kers levels correlate with risk of recurrent stroke and
cardiac death in patients not receiving statins at the time
of presentation. We also demonstrated association be-
tween oxidative stress markers and atherosclerotic
plaque characteristics in this subgroup of patients.
Patients with atherothrombosis have been found to
have relatively high rates of cardiovascular events [8-15].
Given that atherosclerosis is a systemic condition, the
vascular event can occur in the same vascular territory or,
as is frequently the case in stroke patients, in a different
one. Although stroke recurrence in non-cardioembolic
patients is important, no markers are available to identify
patients with high risk of vascular recurrence or vascular-
origin death. In this study we have analyzed three oxida-
tive stress markers (ox-LDL, Cu/Zn SOD and 8OHDG)
as potential markers of risk for recurrent stroke or vascu-
lar death. We also evaluate the relationship between these
markers and other classic markers of risk (IMT, carotid
stenosis grade and plaque echogenicity and surface
characteristics).
First, it is important to note that we found no associ-
ation between ox-LDL, Cu/Zn SOD or 8-OHDG and re-
current stroke in our study group. However when data
was re-analyzed, excluding patients receiving statins, we
found an association between Cu/Zn SOD and 8-OHDG
levels and recurrent stroke and vascular death. In
Figure 1 (See legend on next page.)
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Figure 1 Oxidative stress markers (ox-LDL, Cu/Zn SOD and 8-OHDG) values classified according to: (1A)the primary endpoint (vascular
recurrence) or secondary endpoints (atherosclerotic characteristics); (1B) according to the plaque type or the plaque surface.
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IMT and carotid stenosis grade. We also found differ-
ences in 8-OHDG in relation to atherosclerotic plaque
surface.
The fact that we have found associations between oxida-
tive stress biomarkers and atherosclerosis and vascular re-
currence in patients with non-cardioembolic stroke
without statin treatment but not in the general non-
cardioembolic group of patients, indicates that statin treat-
ment affects oxidative stress marker levels.
Statins are a group of lipid-lowering drugs, 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase inhibi-
tors, used in the prevention and treatment of cardiovascu-
lar diseases. Statins also possess cholesterol-independent
or “pleiotropic” effects which include improvement of
endothelial function, stabilization of atherosclerotic pla-
ques, inhibition of oxidative stress and inflammation, and
a reduction of thrombogenic response [16]. These benefi-
cial effects of statins are, at least in part, mediated by an ef-
fect on eNOS (endothelial Nitric Oxide Synthase) [17-19].
But statins also ameliorate oxidative stress [20] by redu-
cing the expression and/or activity of NADPH oxidase
[21]. These effects may be partly responsible for the anti-
atherogenic action of statins [22-24]. Since statins have
effects on eNOS and NADPH oxidase, it is not surprising
that statins treatment could influence levels of oxidative
stress markers, such as 8-OHDG or Cu/Zn SOD. Further
prospective studies could evaluate the potential of 8-
OHDG or Cu/Zn SOD as prognostic markers.
Our data suggest that oxidative stress marker levels
correlate with outcomes only in patients not treated with
statins. One possible explanation of this is that statins re-
duce oxidative stress.
Conclusions
Specific oxidative stress markers were found to be mar-
kers of atherosclerosis plaque types and vascular recur-
rence. Thus, 8-OHDG and Cu/Zn SOD could be useful
markers to identify patients with high risk of vascular re-
currence or vascular death and 8-OHDG could be useful
to identify particular atherosclerotic plaques characteris-
tics, such as echogenicity, stenosis grade or plaque sur-
face characteristics in patients who are not receiving
statin therapy.
Methods
Study design
From January to July 2009, 42 neurology departments in
Spain performed the ARTICO study. This study includedpatients with non-cardioembolic stroke with age
≥60 years. All patients were admitted to neurology
departments and evaluated by a neurologist before inclu-
sion in the study. All patients were treated according to
the same protocol. The protocol was designed and per-
formed according to the principles of the Helsinki Dec-
laration and was approved by the Ethical Committee of
all the participant hospitals (see list of Artico investiga-
tors in Appendix). Medical history including vascular
risk factors and prior treatment for vascular diseases
were recorded. Blood studies including coagulation para-
meters, brain computed tomography or magnetic reson-
ance, 12-lead ECG, chest radiography, and carotid
ultrasonography were performed at admission. All
patients were treated according to the ARTICO study
protocol [25].
Blood samples, taken on admission, were centrifuged
at 3000 g for 15 minutes, and immediately frozen and
stored at −80°C without any additives.
As markers of endothelial oxidative stress, three mar-
kers were analyzed by ELISA kits according to manufac-
turer’s instructions; one marker of lipid peroxidation,
oxidized LDL (ox-LDL; from Mercodia); one enzymatic
marker, Cu/Zn superoxide dismutase (Cu/Zn SOD, from
Bender Medsystems), and one nucleic acid lesion marker,
8-OH-2deoxiguanosine (8-OHDG).
As markers of atherosclerotic disease, duplex study of
the supraaortic trunk including intima-media thickness
(IMT) measurement; quantification of internal carotid
stenosis; number, morphology and surface characteristics
of carotid plaques; and ankle brachial index (ABI) were
performed at study inclusion. Patients were followed at 6
and 12 months after inclusion. Cardiovascular events, in-
cluding vascular recurrence, ischemic heart disease, symp-
tomatic peripheral arterial disease (PAD), vascular surgery
and death of vascular or non-vascular origin were
recorded. The modified Rankin scale (mRS) was evaluated
at discharge and at 6 and 12 month visits.
Patients were followed at 6 and 12 months after inclu-
sion. Cardiovascular events, including vascular recur-
rence, ischaemic heart disease, symptomatic peripheral
arterial disease (PAD), vascular surgery and death of vas-
cular or non-vascular origin were recorded. The modi-
fied Rankin scale (mRs) was evaluated at discharge and
at 6 and 12 month visits. Additional investigations were
left at the discretion of the investigator in charge of the
patient.
The primary objective of this study was to evaluate the
prognostic value of oxidative stress markers to predict death
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sode of ischemic stroke. As secondary objective, relationship
between IMT measurement; quantification of internal ca-
rotid stenosis; number, morphology and surface characteris-
tics of carotid plaques; ABI, and oxidative stress markers
were analyzed.
Atherothrombotic marker protocol
ABI measurement was performed using an 8 MHz probe
and the same Doppler model (ES-100X) in all centers
after a consensus meeting. Doppler systolic blood pres-
sure at right and left side in both brachial arteries as well
as both the dorsalis pedis artery and posterior tibial ar-
teries were recorded with patients at rest for at least 5
minutes in supine position. The ABI was calculated cen-
trally. Asymptomatic PAD was considered if ABI ≤0.9
and symptomatic PAD when a history of walking impair-
ment, intermittent claudication, ischemic rest pain, and/
or nonhealing wounds was present.
Colour-duplex study of the supraaortic trunks was per-
formed on all patients. Carotid or intracranial artery
stenosis was quantified using established haemodynamic
criteria by echo-Doppler ultrasonography [26]. Each neu-
rosonology department used either their own standar-
dised values or those validated in the literature. Plaques
were classified by echogenicity and surface morphology
in accordance with consensus criteria [27]. IMT was
measured in a still image during diastole in both com-
mon carotid arteries (CCA) at the far wall and at least
1 cm below the bifurcation on a 1 cm plaque-free seg-
ment. The highest of 6 CCA measurements was taken as
the final IMT. To differentiate plaques from just
increased IMT, a plaque was defined when focal thicken-
ing was ≥1.5 mm. IMT was categorized in IMT< 1.1 mm
and IMT ≥ 1.1 mm.
The study was approved by the ethical committee of
each centre and informed consent was obtained from
patients or relatives.
Statistical analysis
Results are expressed as percentage, for categorical vari-
ables, and as mean (SD) or median [quartiles] for con-
tinuous variables, depending on whether they were
normally distributed or not. Proportions between groups
were compared using the chi-square test. To compare
continuous variables between two groups, a Student t-
test was used for variables normally distributed and a
Mann–Whitney test for not normally distributed vari-
ables. To assess the statistical significance of more than
two continuous variables ANOVA test was used.
Multivariate analyses were performed to evaluate the
prognostic value of oxidative stress makers in death or
vascular recurrence. Regression analyses were performed
after adjusting for the main baseline variables in theunivariate analyses (enter approach and probability of
entry p <0.05). Results were expressed as adjusted odds
ratios (OR) with the corresponding 95% confidence
intervals (95% CI). The statistical analysis was performed
using SPSS software v16.0.
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